KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) EBT Margin (2016 - 2025)

Charles River Laboratories International has reported EBT Margin over the past 17 years, most recently at 29.58% for Q4 2025.

  • For Q4 2025, EBT Margin fell 796.0% year-over-year to 29.58%; the TTM value through Dec 2025 reached 2.48%, down 478.0%, while the annual FY2025 figure was 2.48%, 478.0% down from the prior year.
  • EBT Margin for Q4 2025 was 29.58% at Charles River Laboratories International, down from 8.68% in the prior quarter.
  • Over five years, EBT Margin peaked at 22.27% in Q4 2022 and troughed at 29.58% in Q4 2025.
  • A 5-year average of 8.52% and a median of 11.89% in 2022 define the central range for EBT Margin.
  • Biggest five-year swings in EBT Margin: skyrocketed 419bps in 2022 and later crashed -4222bps in 2024.
  • Year by year, EBT Margin stood at 18.08% in 2021, then rose by 23bps to 22.27% in 2022, then dropped by -8bps to 20.59% in 2023, then plummeted by -205bps to 21.62% in 2024, then crashed by -37bps to 29.58% in 2025.
  • Business Quant data shows EBT Margin for CRL at 29.58% in Q4 2025, 8.68% in Q3 2025, and 6.92% in Q2 2025.